Arbutus Biopharma (ABUS) Scheduled to Post Quarterly Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) will release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Arbutus Biopharma to post earnings of ($0.10) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $2.15 million for the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative return on equity of 57.82% and a negative net margin of 401.57%. During the same quarter last year, the business posted ($0.14) EPS. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arbutus Biopharma Price Performance

ABUS stock opened at $2.78 on Tuesday. The stock has a market capitalization of $498.98 million, a P/E ratio of -6.32 and a beta of 2.04. Arbutus Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $3.29. The business has a 50-day moving average of $2.76 and a 200-day moving average of $2.38.

Analysts Set New Price Targets

A number of research firms have weighed in on ABUS. HC Wainwright reduced their price target on Arbutus Biopharma from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 1st. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price on shares of Arbutus Biopharma in a research report on Thursday, April 4th. Finally, Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 1st.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.